Difference between revisions of "Partial antagonist-Amisulpride"

From Psychiatrienet
Jump to: navigation, search
(Created page with "{{Drugswitch | from = Partial antagonist | to = Amisulpride | stop = * '''Day 1-21:''' {{Cont}} * '''Day 22:''' {{Stop}} | start = {{StartStand}} * '''Day 28:''' Reevaluate...")
(No difference)

Revision as of 15:12, 29 October 2021

Partial antagonist

Aripiprazole
Brexpiprazole
Cariprazine

Amisulpride
Type Antipsychotic
Group Atypical AP
links
PubChem 2159
PubMed Amisulpride
Wikipedia Amisulpride

Switch medication from Partial antagonist to Amisulpride.[1] [2]

Nietinrijdenbord.png Stop Partial antagonist
  • Day 1-21: Continue drug at usual dose
  • Day 22: Stop drug
Eenrichtingbord.png Start Amisulpride
  • Day 1-4: approx. 25% of target dose
  • Day 5-8: approx. 50% of target dose
  • Day 9-12: approx. 75% of target dose
  • Day 13: target dose
  • Day 28: Reevaluate dose, if necessary adjust dose
Infobord.png More information
StopAbruptly21StartGradually2.jpg
Nietinrijdenbord.png — Partial antagonist
Eenrichtingbord.png — Amisulpride


  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.